Literature DB >> 17092419

[Effect of treatment with Xuebijing injection on serum inflammatory mediators and Th1/2 of spleen in rats with sepsis].

Shu-wen Zhang1, Cheng-dong Sun, Yan Wen, Cheng-hong Yin.   

Abstract

OBJECTIVE: To study the effect of treatment with Xuebijing injection on pro- or anti-inflammatory response and pathologic changes in immune organs in rats with sepsis.
METHODS: Sepsis was reproduced in rats by cecal ligation and puncture. Rats were divided into four groups i.e. sham operation, sepsis, sepsis with levofloxacin treatment, and Xuebijing treatment groups. Blood samples were collected at 3, 24 and 72 hours after model was reproduced. Enzyme linked immunoadsorbent assay (ELISA) was used to determine the levels of serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10), expression level of spleen Th1/Th2 was assessed by FACS flow cytometer, and the pathological changes in immunological organs were examined.
RESULTS: The results showed that the levels of Th1/Th2 and TNF-alpha, IL-10 were elevated in early period of sepsis, but lowered in late period of sepsis. Xuebijing could decrease the level of Th1/Th2, which showed an increase at 72 hours. Xuebijing could lower the levels of TNF-alpha and IL-10, rendering a balance of pro- and anti-inflammatory response.
CONCLUSION: There is a dissonance in immunological function in sepsis, showing a depression in specific immunological function, but an exaggeration in non-specific immunological function. Xuebijing can obviously ameliorate the immunological disturbance in sepsis of rat.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17092419

Source DB:  PubMed          Journal:  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue        ISSN: 1003-0603


  8 in total

1.  Xuebijing injection treatment inhibits vasopermeability and reduces fluid requirements in a canine burn model.

Authors:  F-B Tang; Y-L Dai; S Hu; L-Q Ma; J-Y Li; H-P Zhang; W-H Zhang; Y-G Li; H-B Wang; H-Y Lin; Q Hu; L Li
Journal:  Eur J Trauma Emerg Surg       Date:  2017-01-09       Impact factor: 3.693

2.  Effects of peritoneal macrophage autophagy on the immune function of sepsis mice.

Authors:  Da-Long Zhang; Shun-Wen Zhang; Qing Hong Cheng; Fang Wu; Jiang-Dong Wu; Jie Zhang; Jiang-Tao Dong; Hui-Yun Zhu; Shuai Zhang; Qing-Qing Wu; Wan-Jiang Zhang
Journal:  Am J Clin Exp Immunol       Date:  2017-06-15

3.  Intravenous injection of Xuebijing attenuates acute kidney injury in rats with paraquat intoxication.

Authors:  Jia-Jun Xu; Jian-Tao Zhen; Li Tang; Qing-Ming Lin
Journal:  World J Emerg Med       Date:  2017

4.  The effects of paeoniflorin injection on soluble triggering receptor expressed on myeloid-1 (sTREM-1) levels in severe septic rats.

Authors:  Xiao-Rong Liu; Jie Xu; Yi-Min Wang; Ming-Suo Ji; Fu-Shan Liu
Journal:  Korean J Physiol Pharmacol       Date:  2016-10-28       Impact factor: 2.016

Review 5.  Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms.

Authors:  Kai Huang; Pan Zhang; Zhenghao Zhang; Ji Youn Youn; Chen Wang; Hongchun Zhang; Hua Cai
Journal:  Pharmacol Ther       Date:  2021-03-31       Impact factor: 13.400

6.  Xuebijing Protects Rats from Sepsis Challenged with Acinetobacter baumannii by Promoting Annexin A1 Expression and Inhibiting Proinflammatory Cytokines Secretion.

Authors:  Xian-Di He; Yan Wang; Qiong Wu; Hua-Xue Wang; Zhen-Dong Chen; Rong-Sheng Zheng; Zi-Shu Wang; Jun-Bin Wang; Yan Yang
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-28       Impact factor: 2.629

7.  The potential insights of Traditional Chinese Medicine on treatment of COVID-19.

Authors:  Tong Tong; Ying-Qi Wu; Wei-Jian Ni; Ai-Zong Shen; Sheng Liu
Journal:  Chin Med       Date:  2020-05-24       Impact factor: 5.455

Review 8.  Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China.

Authors:  Wei Zhuang; Zheng Fan; Yanqi Chu; Haizheng Wang; Ying Yang; Li Wu; Nan Sun; Ge Sun; Yuqiao Shen; Xiaolan Lin; Guiming Guo; Shengyan Xi
Journal:  Front Pharmacol       Date:  2020-07-17       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.